Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 5/20 | 0.45 |
| ▸ | DRD3 | P35462 | 5/20 | 0.45 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.41 |
| ▸ | DRD4 | P21917 | 2/20 | 0.40 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.40 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | ACHE | P22303 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6334840 | 1.00 | DRD2 (0.45) | DRD2DRD3CYP19A1DRD4MTNR1A | |
| SCHEMBL6343665 | 0.91 | DRD2 (0.46) | DRD2DRD3CYP19A1DRD4MTNR1A | |
| SCHEMBL2700596 | 0.84 | SIGMAR1 (0.46) | DRD2DRD3CYP19A1DRD4MTNR1A | |
| SCHEMBL5216589 | 0.83 | DRD2 (0.49) | DRD2DRD3CYP19A1DRD4MTNR1A | |
| SCHEMBL5216890 | 0.83 | DRD2 (0.49) | DRD2DRD3CYP19A1DRD4MTNR1A | |
| SCHEMBL6619572 | 0.77 | DRD2 (0.43) | DRD2DRD3CYP19A1DRD4MTNR1A | |
| SCHEMBL6335390 | 0.74 | CA1 (0.43) | DRD2DRD3CYP19A1DRD4MTNR1A | |
| SCHEMBL6345240 | 0.74 | CA1 (0.43) | DRD2DRD3CYP19A1DRD4MTNR1A | |
| SCHEMBL5216881 | 0.73 | DRD2 (0.65) | DRD2DRD3CYP19A1DRD4MTNR1A | |
| SCHEMBL5216586 | 0.73 | DRD2 (0.65) | DRD2DRD3CYP19A1DRD4MTNR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1453805-A1 | 4-PIPERIDINYL ALKYLAMINE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-09-08 | — | — | EP | disclosed |
| US-20040092554-A1 | 4-piperidinyl alkyl amine derivatives as muscarinic receptor antagonists | BROTHERTON-PLEISS CHRISTINE E (US) | 2004-05-13 | — | — | US | disclosed |
| US-20030162780-A1 | 4-PIPERIDINYL ALKYL AMINE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | SYNTEX (U.S.A.) LLC, NAME CHANGED TO ROCHE PALO ALTO LLC | 2003-08-28 | — | — | US | disclosed |
| WO-2003048124-A1 | 4-PIPERIDINYL ALKYLAMINE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162780-A1 | 4-PIPERIDINYL ALKYL AMINE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | CHRM1, CHRM3, CHRM2 | DRD2 50/4885DRD3 56/4885CYP19A1 1893/4885 |
| US-20040092554-A1 | 4-piperidinyl alkyl amine derivatives as muscarinic receptor antagonists | CHRM1, CHRM3, CHRM2 | DRD2 50/4885DRD3 56/4885CYP19A1 1893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.